{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.8","upperLimit":"12.7","value":"11.13"},{"groupId":"OG001","lowerLimit":"7.2","upperLimit":"11.2","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"209"}],"units":"Participants"}],"description":"For participants who demonstrate CR or PR, DOR is defined as the time from first response (CR or PR) to subsequent disease progression or death from any cause, whichever occurs first. DOR was determined for first course pembrolizumab in the Global Cohort. Per statistical analysis plan, participants in the Japan-specific SOX Cohort were not included in the efficacy analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 200 mg pembrolizumab IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy.","id":"OG000","title":"Global Pembrolizumab + Standard of Care First Course"},{"description":"Participants received matched placebo to pembrolizumab IV Q3W plus trastuzumab (8mg/kg loading dose, 6mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy.","id":"OG001","title":"Global Standard of Care First Course"}],"paramType":"MEDIAN","populationDescription":"All randomized Global Cohort participants in the Pembrolizumab First Course arm and SOC arm and who had CR or PR per RECIST 1.1 as assessed by BICR were included in this analysis. Per statistical analysis plan, participants in the Japan-specific SOX Cohort were not included in the efficacy analysis.","reportingStatus":"POSTED","timeFrame":"Up to 63 months","title":"Duration of Response (DOR) Per RECIST 1.1 Assessed by BICR","type":"SECONDARY","unitOfMeasure":"Months"}